Abatacept in B7-1-positive proteinuric kidney disease

Chih Chuan Yu, Alessia Fornoni, Astrid Weins, Samy Hakroush, Dony Maiguel, Junichiro Sageshima, Linda Chen, Gaetano Ciancio, Mohd Hafeez Faridi, Daniel Behr, Kirk N. Campbell, Jer Ming Chang, Hung Chun Chen, Jun Oh, Christian Faul, M. Amin Arnaout, Paolo Fiorina, Vineet Gupta, Anna Greka, George W. BurkePeter Mundel

Research output: Contribution to journalArticlepeer-review

321 Scopus citations


Abatacept (cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion protein [CTLA-4-Ig]) is a costimulatory inhibitor that targets B7-1 (CD80). The present report describes five patients who had focal segmental glomerulosclerosis (FSGS) (four with recurrent FSGS after transplantation and one with primary FSGS) and proteinuria with B7-1 immunostaining of podocytes in kidney-biopsy specimens. Abatacept induced partial or complete remissions of proteinuria in these patients, suggesting that B7-1 may be a useful biomarker for the treatment of some glomerulopathies. Our data indicate that abatacept may stabilize β1-integrin activation in podocytes and reduce proteinuria in patients with B7-1-positive glomerular disease.

Original languageEnglish (US)
Pages (from-to)2416-2423
Number of pages8
JournalNew England Journal of Medicine
Issue number25
StatePublished - 2013
Externally publishedYes

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Abatacept in B7-1-positive proteinuric kidney disease'. Together they form a unique fingerprint.

Cite this